Proteomics Market Development And Business Intelligence
Summary
- Major factors influencing the growth of the market.
- Leading players & Business Strategies.
- Geographic Overview.
Market growth influenced due to following factors-
- An increase in the research activity, especially in the area of personalized medicine and drug discovery.
- The increasing R&D expenditure by pharmaceutical and biotechnology companies
- Increasing government funding, and technological advancements
Global market size-
According to research report Global proteomics market is projected to reach USD 55.9 billion by 2026 from USD 25.9 billion in 2021, at a CAGR of 16.6% during the forecast period.
For more details, Download PDF Brochure Here
Leading Players-
The major players operating in this market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Bruker Corporation (US), Danaher Corporation (US), GE Healthcare (US), Luminex Corporation (US), PerkinElmer Inc. (US), Waters Corporation (US), Illumina, Inc. (US), Eurofins Scientific (Luxembourg), QIAGEN Bioinformatics (Netherlands), Creative Proteomics (US), Promega Corporation (US), Sengenics (Singapore), Biomax Informatics AG (Germany), MS Bioworks LLC (US), WuXi NextCODE (CHINA), Fios Genomics Ltd. (UK), GENEWIZ (US), Biognosys AG (Switzerland), Bioproximity (Switzerland), MRM Proteomics Inc. (Canada), Integrated Proteomics Applications (US), Poochon Scientific, LLC (US), Proteome Factory AG (Germany), VProteomics (India), HORIBA, Ltd. (Japan), and Applied Biomics, Inc. (US).
Geographic Overview -
The global proteomics market is segmented into North America, Europe, the Asia Pacific, Latin America and Middle East & Africa. In 2020, North America accounted for the largest market share in the proteomics market. This can be attributed to the increasing investments in the development of structure-based drug design, growing research in the field of omics, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.